VGG7185A1286 - Common Stock
PORTAGE BIOTECH INC
NASDAQ:PRTG (6/28/2024, 7:21:49 PM)
Premarket: 0.1754 -0.04 (-17.34%)0.2122
-0.01 (-6.11%)
Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. The firm is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.
PORTAGE BIOTECH INC
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG1110
P: 4167377600
CEO: Ian Walters
Employees: 7
Website: https://portagebiotech.com/
It's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!
Here you can normally see the latest stock twits on PRTG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: